305 related articles for article (PubMed ID: 35403971)
21. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
22. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
[No Abstract] [Full Text] [Related]
23. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
24. Hairy cell leukemia: a 'hair-raising' update.
Topp ZZ; Saven A
Expert Rev Hematol; 2014 Oct; 7(5):659-69. PubMed ID: 25148599
[TBL] [Abstract][Full Text] [Related]
25. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
26. Hairy Cell Leukemia: Where Are We in 2023?
Mendez-Hernandez A; Moturi K; Hanson V; Andritsos LA
Curr Oncol Rep; 2023 Aug; 25(8):833-840. PubMed ID: 37097545
[TBL] [Abstract][Full Text] [Related]
27. Hairy cell leukemia: Past, present and future.
Getta BM; Park JH; Tallman MS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
[TBL] [Abstract][Full Text] [Related]
28. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
29. New insights in the management of patients with hairy cell leukemia.
Cornet E; Damaj G; Troussard X
Curr Opin Oncol; 2015 Sep; 27(5):371-6. PubMed ID: 26154707
[TBL] [Abstract][Full Text] [Related]
30. Chemoimmunotherapy for hairy cell leukemia.
Ravandi F
Best Pract Res Clin Haematol; 2015 Dec; 28(4):230-5. PubMed ID: 26614901
[TBL] [Abstract][Full Text] [Related]
31. My treatment approach to hairy cell leukemia.
Naik RR; Saven A
Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
[TBL] [Abstract][Full Text] [Related]
32. The pharmacological management of hairy cell leukemia.
Ramos Perez J; Ravandi-Kashani F
Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
[TBL] [Abstract][Full Text] [Related]
33. [Hairy cell leukemia: What are the best treatment options for relapsed or refractory patients?].
Troussard X; Maitre E; Paillassa J
Bull Cancer; 2021; 108(7-8):771-778. PubMed ID: 34023063
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman RJ; Arons E
Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
[TBL] [Abstract][Full Text] [Related]
35. Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hairy cell leukemia.
Chihara D; Kreitman RJ
Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
[TBL] [Abstract][Full Text] [Related]
37. Update on hairy cell leukemia.
Kreitman RJ; Arons E
Clin Adv Hematol Oncol; 2018 Mar; 16(3):205-215. PubMed ID: 29742076
[TBL] [Abstract][Full Text] [Related]
38. Potential breakthroughs with investigational drugs for hairy cell leukemia.
Robak T; Wolska A; Robak P
Expert Opin Investig Drugs; 2015; 24(11):1419-31. PubMed ID: 26329588
[TBL] [Abstract][Full Text] [Related]
39. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
Falini B; Martelli MP; Tiacci E
Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
[TBL] [Abstract][Full Text] [Related]
40. BRAF in the cross-hairs.
Geyer MB; Abdel-Wahab O; Tallman MS
Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
